基于RBD的高 afinity ACE2对抗剂限制了SARS-CoV-2在上下呼吸道的复制
bioRxiv : the preprint server for biology
|July 28, 2023
概括
一种新型蛋白质,RBD-62,通过增强ACE2结合,提供对严重的SARS-CoV-2疾病的变异无关保护. 这种治疗剂可以保护免受三角洲变种的侵袭,但不妨碍免疫记忆或诱导抗药免疫力.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 生物医学工程 生物医学工程
背景情况:
- SARS-CoV-2 进化突变,逃避免疫力和抗病毒治疗.
- 需要一种通用治疗剂来对抗严重疾病,而无需病毒压力.
研究的目的:
- 为了评估气溶液RBD-62的疗效,一种具有增强ACE2结合的蛋白质,作为对SARS-CoV-2的变异无关治疗药物.
主要方法:
- rhesus 被感染了SARS-CoV-2 德尔塔变种.
- 动物同时接受了气溶RBD-62.2的治疗.
- 评估了上空气道和下空气道的保护.
主要成果:
- 在上空和下空气道上,RBD-62提供了同等的保护.
- 治疗并没有阻碍对Delta变种的记忆反应的发展.
- RBD-62没有引起抗药免疫力.
结论:
- RBD-62证明了预防由病毒性SARS-CoV-2变种引起的严重疾病的概念证明.
- 这种蛋白质代表了一种有前途的变异不可知治疗策略.
- RBD-62提供了一种独特的保护机制,与目前的疫苗不同.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
692
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
692
Antiasthma Drugs: β2-Adrenoceptor Agonists
308
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
308
Antihypertensive Drugs: Angiotensin II Receptor Blockers
782
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
782
Structure-Activity Relationships and Drug Design
770
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
770
Antiasthma Drugs: Muscarinic Receptor Antagonists
340
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
340
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463


